CD47 and neoplasm: Therefore, CD47 blockage represents a promising avenue to create pro-inflammation TME that could augment anti-tumor response by enhancing M1 macrophage response [83] which may be particularly effective for GBM treatment considering the surprisingly high composition of TAMs, 30–50% of tumor mass.